STS/EACTS Latin America Cardiovascular Surgery Conference September 21-22, 2017 | Cartagena, Colombia

info@cardiovascularsurgeryconference.org www.CardiovascularSurgeryConference.org

The Heart Team and Management of AS

David S. Bach, MD
Professor of Medicine
Park W Willis III Collegiate Professor of
Cardiovascular Medicine
University of Michigan; Ann Arbor, MI; USA







Presenter Disclosure Information

- Consulting fees and honoraria
 - ACC Foundation
 - Biomedical Solutions
 - Edwards Lifesciences
 - Medtronic, Inc.
 - St. Jude Medical, Inc.

- (Significant level)
- (Moderate level)
- (Significant level)
- (Significant level)
- (Moderate level)


- Research support
 - Edwards Lifesciences
 - Medtronic, Inc.
 - St. Jude Medical, Inc.

(Significant level)

(Moderate level)


(Significant level)

Natural History of Aortic Stenosis / AVR



Ross and Braunwald. Circulation 1968;38:V61-V7 Piérard S, et al. Ann Thorac Surg 2014;97:803-10


TAVR Growth (European Union 2007-2011)



Mylotte D, et al. J Am Coll Cardiol 2013;62:210-9

TAVR vs. SAVR (Germany 2007 - 2013)

32,581 TAVR and 55,992 SAVR




Reinöhl J, et al. New Engl J Med 2015;373:2438-47


AS Management Complexity in 2017

- AS severity and characterization:
 - Discrepant gradients, valve area
 - Gradient (high/low), flow (normal/low), EF (normal/low)
 - AV and annular morphology (tricuspid vs. bicuspid AV)
 - Requirement for multi-modality imaging
- Symptoms referable to AS? Role of exercise testing.
- Patient characteristics: age, comorbidities, frailty...
- Therapeutic options (SAVR, TAVR [access], BAV).
- Procedural assessment: hostile chest, vascular access...


All-Cause Mortality at 30 Days PARTNER I and PARTNER II Trials (Overall and Transfemoral)




All Strokes at 30 Days PARTNER I and PARTNER II Trials (Overall and Transfemoral)



U.S. TVT Practice Trends 2012 to 2014 STS/ACC TVT Registry




TAVR Procedural Experience vs. Outcomes STS/ACC TVT Registry



Carroll JD, et al. J Am Coll Cardiol 2017;70:29-41

SAVR vs. TAVR (AHA/ACC 2017 Focused Update)



Nishimura RA, et al. J Am Coll Cardiol 2017;70:252-89

Heart Valve Team Composition and Purpose

HVT Composition

- Cardiologist
- Cardiac surgeon
- Structural interventionalist
- Imaging specialists
 - Echo, CT, MRI
- Anesthesiologists
- Nurses

HVT Purpose

- AS severity and characterization
 - AS severity
 - Gradients, flow, EF
 - · Valve and annular morphology
- Symptoms referable to AS
- Patient risk assessment
- Therapeutic options
- Therapeutic plans

Heart Valve Team and Patient Management

